Clinical trials: Liver Fibrosis/NASH
Nonalcoholic Steatohepatitis, Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
- Trial name
- NASH (NCT05011305)
- Testing
- Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg
- Where
- 129 sites in United States, Argentina and 2 more
- Volunteers
- 189 people
- Sponsor
- Zydus Therapeutics Inc.
Steatohepatitis
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
The main aim of this study is to evaluate the safety and tolerability of ontamalimab in participants with a liver disease called nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with…
- Trial name
- NCT07052682
- Testing
- Ontamalimab
- Where
- 15 sites in United States
- Volunteers
- 11 people
- Sponsor
- Takeda
Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome
In this study, we aim to identify gut microbiomes specific to patients with chronic refractory liver disease and to conduct a gut-liver axis study on the pathogenesis and disease progression.
- Conditions
- Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Liver Abscess
- Trial name
- LGAS (NCT06519162)
- Where
- South Korea
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Chungnam National University Hospital
Diabetes Mellitus, Type 2, Metabolic Associated Fatty Liver Disease
Correlation Between Serum Nociceptin and Sympathetic Nerve Activity in Diabetic Patients With MAFLD
This observational study aims to investigate the relationship between serum nociceptin levels and sympathetic nervous system activity in patients with both type 2 diabetes mellitus (T2DM) and metabolic associated fatty liver…
- Trial name
- NCT07663682
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Second Hospital of Shanxi Medical University
Liver Fibrosis Due to NASH
Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH
The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH).
- Trial name
- NASH (NCT01672879)
- Testing
- SIM
- Where
- 59 sites in United States, Canada and 6 more
- Volunteers
- 259 people
- Sponsor
- Gilead Sciences
HCC, Cirrhosis, Liver
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)
The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in…
- Conditions
- HCC, Cirrhosis, Liver, NAFLD, HBV
- Trial name
- GALAD (NCT05781568)
- Testing
- Biomarker dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
NAFLD/MAFLD, Liver Fibrosis
Impact of Fluid Status on Liver Elastography and T1-mapping Results in Patients Undergoing CMR.
Correlation between CMR T1-times, liver T1-times, fibroscan and fluid status to identify the correlation and pathogenesis of liver disease in patients with heart disease.
- Conditions
- NAFLD/MAFLD, Liver Fibrosis, CMR
- Trial name
- NCT05239260
- Testing
- CMR
- Where
- Austria
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Fatty Liver Disease
Prevalence of Advanced Fibrosis in Patients Living With HIV
Monocentric, cross-sectional study to define the prevalence of advanced fibrosis in an HIV infected outpatient population. Follow-up over 10 years to assess clinical relevance.
- Trial name
- FLASH (NCT04066608)
- Where
- 2 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
The aim is to determine the metabolic factors, host immune factors, and medical imaging data associated with the development of HepatoCellular Carcinoma (HCC) in patients with alcohol-related liver disease or dysmetabolic…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Alcohol-related Liver Disease, Cirrhosis, Liver
- Trial name
- CHALNA2 (NCT05623150)
- Testing
- Liver biopsy
- Where
- France
- Volunteers
- 710 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Non-Alcoholic Fatty Liver Disease, Childhood Obesity
Clinical Epidemiology of NAFLD in Children and Adolescents
Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing alongside overweight and obesity, not only in adults but also in children and adolescents.
- Trial name
- LiverKids (NCT05526274)
- Testing
- Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
- Where
- Spain
- Volunteers
- 2,866 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or…
- Trial name
- MAESTRO-NASH (NCT03900429)
- Testing
- MGL-3196, Liver Biopsy
- Where
- 247 sites in United States, Australia and 14 more
- Volunteers
- 1,759 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Metabolic- Associated Fatty Liver Disease (MAFLD)
MAFLD Fibrosis Score for Detecting Fibrotic NASH in MAFLD Egyptian Patients
Metabolic-associated fatty liver disease (MAFLD), is a metabolic stress-induced liver injury characterized by diffuse hepatocyte macrovesicular fatty infiltration.
- Trial name
- NCT06492369
- Where
- Egypt
- Volunteers
- 382 people
- Sponsor
- Tanta University
NASH
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05327127
- Testing
- K-877-ER, CSG452
- Where
- 77 sites in United States, Argentina and 4 more
- Volunteers
- 228 people
- Sponsor
- Kowa Research Institute, Inc.
Non-alcoholic Fatty Liver Disease
Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression
Non-alcoholic fatty liver disease (NAFLD) is a common disorder, affecting ~30% of people in the general population and up to 96% of obese individuals.
- Trial name
- NCT02267148
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- UNC Nutrition Research Institute
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
Acquired immunodeficiency syndrome (AIDS) remains a severe global infectious disease, with over 38 million people living with HIV and around 35 million cumulative deaths worldwide by 2023; approximately 1.24 million HIV-positive…
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fibrosis, HIV/AIDS
- Trial name
- NCT05330923
- Testing
- Liver Quantitative Ultrasound
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Metabolic Syndrome X, Fatty Liver
Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients
The objective of the study is to evaluate an ultraportable ultrasound device, Hepatoscope, for the non-invasive assessment of hepatic steatosis in patients with metabolic-dysfunction associated liver diseases (MASLD), by…
- Conditions
- Metabolic Syndrome X, Fatty Liver, MASH - Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- Trial name
- ACOUSTIQ (NCT06661655)
- Testing
- Liver ultrasound
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- E-Scopics
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NAFLD, NASH
LITMUS Imaging Study
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD).
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT05479721
- Where
- 18 sites in United States, Finland and 8 more
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Chronic Liver Disease, Fibrosis, Liver
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
The aims of this study are to assess the performance of the non-invasive Electrical Impedance Technology (EIT) in evaluating the liver fibrosis stage in patients with chronic liver diseases, in comparisons with a liver biopsy…
- Conditions
- Chronic Liver Disease, Fibrosis, Liver, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03492879
- Testing
- EIT Technology
- Volunteers
- 210 people
- Sponsor
- Prof. Ziv Ben-Ari MD
Cushing Syndrome, Fatty Liver Disease
NAC- NAFLD And Cushing
Cushing's Syndrome is a rare disease resulting from prolonged exposure to high levels of circulating cortisol. Clinical manifestations are variable but many patients present a metabolic syndrome (abdominal obesity, insulin…
- Trial name
- NAC (NCT05881005)
- Testing
- hepatic MRI
- Where
- 7 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers